会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • FATTY ACID BINDING PROTEINS AS DRUG TARGETS FOR MODULATION OF ENDOCANNABINOIDS
    • 脂肪酸结合蛋白作为用于调节内联蛋白的药物目标
    • WO2010083532A1
    • 2010-07-22
    • PCT/US2010021431
    • 2010-01-19
    • RES FOUNDATON OF STATE UNIVERSDEUTSCH DALEKACZOCHA MARTINGLASER SHERRYE
    • DEUTSCH DALEKACZOCHA MARTINGLASER SHERRYE
    • G01N33/53
    • G01N33/948G01N2500/02G01N2500/04G01N2500/10
    • The invention provides a method of modulating the level of an endocannabinoid in a subject in need thereof comprising administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate binding of the endocannabinoid with an intracellular FABP. The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate expression of an intracellular FABP. The invention also provides a method of identifying an agent for treatment of a neurological disorder comprising testing the agent for its ability to modulate the interaction of an endocannabinoid with an intracellular FABP. The invention also relates to modulation of levels of fatty acid amides for treatment or amelioration of diseases or disorders by modulating binding of the fatty acid amides to fatty acid binding proteins. In one embodiment, the fatty acid binding protein is one or more of FABP3, FABP5, and FABP7. In one embodiment, the level of an endocannabinoid is modulated.
    • 本发明提供调节有需要的受试者中内源性大麻素水平的方法,包括施用有效量的抑制内源性大麻素与细胞内脂肪酸结合蛋白(FABP)相互作用的药剂。 本发明还提供了鉴定用于调节受试者中内源性大麻素水平的药剂的方法,包括测试该药剂调节内源性大麻素与细胞内FABP结合的能力。 本发明还提供了鉴定用于调节受试者中内源性大麻素水平的药剂的方法,所述方法包括测试所述药剂调节细胞内FABP表达的能力。 本发明还提供鉴定用于治疗神经障碍的药剂的方法,包括测试该药剂调节内源性大麻素与细胞内FABP的相互作用的能力。 本发明还涉及通过调节脂肪酸酰胺与脂肪酸结合蛋白的结合来调节用于治疗或改善疾病或病症的脂肪酸酰胺的水平。 在一个实施方案中,脂肪酸结合蛋白是FABP3,FABP5和FABP7中的一种或多种。 在一个实施方案中,调节内源性大麻素的水平。